What You Should Know:
– InformedDNA®, a precision health company focused on revolutionizing the application of genomic insights, has announced its acquisition of Coriell Life Sciences, a provider of pharmacogenomic services and clinical decision support. Financial details of the acquisition were not disclosed.
– The strategic acquisition significantly expands InformedDNA’s capabilities, offering patients, providers, and payers broader access to genetic insights for more personalized and data-driven treatment and medication decisions.
Coriell’s Pharmacogenomics Capabilities
Coriell Life Sciences, based in Philadelphia, specializes in combining pharmacogenomics—the study of how genes affect medication response—with precision medicine to deliver tailored diagnosis and treatment plans. Their services cater to a wide range of clients, including large employers, health plans, payer organizations, health systems, and research institutions.
The company’s key offerings include:
- Corigen®: A population-scale medication risk management program designed to help organizations ensure patients receive the most effective medications for optimal outcomes.
- Expert Pharmacogenomic Research Analysis: Services provided to laboratories for in-depth analysis.
DNAimpact Integration
By integrating Coriell Life Sciences’ pharmacogenomic services into InformedDNA’s existing genetic test interpretation and counseling capabilities, specifically within InformedDNA’s precision health platform, DNAimpact™, the combined entity will provide a more comprehensive suite of precision health solutions. This integration will enable the identification of more targeted and effective therapies based on individual genomic profiles, coupled with interactive education and access to clinical experts.
